⁹⁰Y Radioembolization

References

• U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Available at online at: www.cdc.gov/uscs. Last accessed July 17, 2014.
   Google Scholar
• Centers for Disease Control and Prevention. Colorectal cancer screening rates remain low. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2013. Available at www.cdc.gov/media/releases/2013/p1105-colorectal-cancer-screening.html. Last accessed July 17, 2014.
   Google Scholar
• Landis, SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1999;49(1): 8–31.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures, 2013. Available online at: www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013. Last accessed July 17, 2014.
   Google Scholar
• SIR-Spheres microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).
   Google Scholar
• Jakobs TF, Hoffman RT, Dehm K, Trumm C, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19(8):1187–1195.
   PubMed Web of Science ®Google Scholar
• Gray B, van Hazel G, Hope M, Burton M, et al. Randomized trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–1720.
   PubMed Web of Science ®Google Scholar
• van Hazel G, Blackwell A, Anderson J, Price D, et al. Randomized phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.
   PubMed Web of Science ®Google Scholar
• Sharma R, van Hazel G, Morgan B, Berry DP, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–1106.
   PubMed Web of Science ®Google Scholar
• van Hazel GA, Pavlakis N, Goldstein D, Olver IN, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27(25):4089–4095.
   PubMed Web of Science ®Google Scholar
• Kennedy A, Coldwell D, Nutting C, Murthy R, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. International J Rad Oncol, Bio, and Phys. 2006; 65(2):412–425.
   PubMed Web of Science ®Google Scholar
• Hoffman RT, Jakobs TF, Kubisch C, Stemmler HJ, et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease—Is it feasible? Eur J Radiol. 2010:74(1):199–205.
   Web of Science ®Google Scholar
• Whitney R, Tatum C, Hahl M, Ellis S, et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. 2011;166(2):236–240.
   PubMed Web of Science ®Google Scholar
• Seidensticker R, Denecke T, Kraus P, Seidensticker M, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Interv Radiol. 2012;35(5):1066–1073.
   PubMed Web of Science ®Google Scholar
• Kennedy AS, Ball D, Cohen SJ, Cohn M, et al. Safety and efficacy of resin 90Y-microspheres in 548 patients with colorectal liver metastases progressing on systemic chemotherapy. ASCO Gastrointestinal Cancers Symposium. 2013; Abs. 264.
   Google Scholar
• Cosimelli M, Golfieri R, Cagol PP, Carpanese L, et al. Italian Society of Locoregional Therapies in Oncology. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103(3):324–331.
   PubMed Web of Science ®Google Scholar
• Kennedy AS, Ball D, Cohen SJ, Cohn M, et al. Hepatic imaging response to 90Y-microsphere therapy administered for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. ASCO Gastrointestinal Cancers Symposium. 2013; Abs. 270.
   Google Scholar
• Kennedy A, Ball D, Cohen SJ, Cohn M, et al. Safety and efficacy of ⁹⁰Y resin microspheres in elderly (≥70 years) compared to younger patients with colorectal liver metastases (mCRC). Poster presented at: American Society of Clinical Oncology annual meeting; June 2013; Chicago.
   Google Scholar
• Kennedy AS, Ball D, Cohen SJ, Cohn M, et al. Pre-90Y hepatic radiotherapy hemoglobin and liver functions predict overall survival in unresectable chemotherapy refractory metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium 2014; Abs. 292.
   Google Scholar
• Kennedy A, Nag S, Salem R, Murthy R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23.
   PubMed Web of Science ®Google Scholar
• Bester L, Meteling B, Pocock N, Pavlakis N, et al. Radioembolization versus standard care of hepatic metastases: Comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23(1):96–105.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, Siena S, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–212.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Prenen H, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28), 3499–3506.
   PubMed Web of Science ®Google Scholar
• Bennouna, Sastre J, Arnold D, Osterlund P, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncology. 2013;14(1):29–37.
   PubMed Web of Science ®Google Scholar
• Kennedy A, Clipp R, Christensen D. First in man fractal methodology to model both the hepatic arterial tree and tumor microvasculature for 90Y-microsphere brachytherapy. ASCO Gastrointestinal Cancers Symposium. 2014; Abs. 248.
   Google Scholar